KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) Income from Continuing Operations (2018 - 2025)

Adaptive Biotechnologies' Income from Continuing Operations history spans 8 years, with the latest figure at 12773000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 62.12% year-over-year to 12773000.0; the TTM value through Dec 2025 reached 57906000.0, up 63.72%, while the annual FY2025 figure was 59457000.0, 62.75% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 12773000.0 at Adaptive Biotechnologies, down from 10290000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 10290000.0 in Q3 2025 and bottomed at 69467000.0 in Q4 2023.
  • The 5-year median for Income from Continuing Operations is 46890500.0 (2024), against an average of 42344300.0.
  • The largest annual shift saw Income from Continuing Operations plummeted 89.88% in 2023 before it soared 132.06% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 61357000.0 in 2021, then soared by 40.38% to 36584000.0 in 2022, then tumbled by 89.88% to 69467000.0 in 2023, then skyrocketed by 51.46% to 33717000.0 in 2024, then surged by 62.12% to 12773000.0 in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Income from Continuing Operations are 12773000.0 (Q4 2025), 10290000.0 (Q3 2025), and 25593000.0 (Q2 2025).